Sphenopalatine Block vs Dexmedetomidine Infusion in Trans Nasal Endoscopic Pituitary Surgery

NAActive, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Sphenopalatine Ganglion Nerve BlockTransnasal Endoscopic Pitutary Surgery
Interventions
PROCEDURE

Sphenopalatine Ganglion Block

patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.

DRUG

Dexmedetomidine

patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.

OTHER

General Anesthesia (control group)

patients will be operated under general anesthesia including routine protocol for these cases

Trial Locations (1)

Unknown

Zagazig Univesity Hospital, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT06639659 - Sphenopalatine Block vs Dexmedetomidine Infusion in Trans Nasal Endoscopic Pituitary Surgery | Biotech Hunter | Biotech Hunter